Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

NCT07179380 is registered in ClinicalTrials.gov with Insmed Incorporated as lead sponsor.

NCT NCT07179380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07179380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
Lead sponsor
Insmed Incorporated
Phase
Phase 3
Overall status
Recruiting
Start date
January 7, 2026
Completion date
December 30, 2028
Enrollment
344 (estimated)
Sites
186

Conditions

As the registry lists them; a condition with its own page is linked.

interstitial lung disease, pulmonary hypertension